Baird analyst Joe Vruwink maintains Ansys (NASDAQ:ANSS) with a Outperform and raises the price target from $295 to $305.
Analyst Views West Pharmaceutical’s Q4 Earnings Impressive Despite Headwinds
West Pharmaceutical Services Inc (NYSE:WST) reported Q4 2022 net sales of $708.7 million, down 3%, and organic net sales growth…